Repository logo
 
Publication

Dexamethasone Intravitreal Implant for Treatment of Patients with Recalcitrant Macular Edema Resulting from Irvine-Gass Syndrome

2013-05-07Journal article Open access
Simple item page
dc.contributor.authorDutra Medeiros, M
dc.contributor.authorNavarro, R
dc.contributor.authorGarcia-Arumí, J
dc.contributor.authorMateo, C
dc.contributor.authorCorcóstegui, B
dc.date.accessioned2017-10-24T14:53:56Z
dc.date.available2017-10-24T14:53:56Z
dc.date.issued2013-05-07
dc.description.abstractPURPOSE: To evaluate the effectiveness of a single intravitreal injection of dexamethasone implant, over 6 months in patients with recalcitrant CME due to Irvine-Gass syndrome. METHODS: Retrospective review of the medical records of nine patients with refractory macular edema (ME) due to Irvine-Gass syndrome, who underwent a single intravitreal injection of dexamethasone implant, Ozurdex, between November 2010 and January 2012, at the Instituto de Microcirurgia Ocular, Barcelona, Spain. All patients underwent a complete ophthalmic evaluation, including best-corrected visual acuity (BCVA) using standardized ETDRS charts, tonometry, fluorescein angiography, and spectral-domain optical coherence tomography with foveal thickness (FT) measurement. RESULTS: The mean duration of CME before treatment with Ozurdex was 9.1 months (range, 6-13 months). At baseline, the mean FT was 542.22 ± 134.78 μm. Mean (SD) values of FT did decrease to 350.88 ± 98.71 μm (P = 0.001) at month 1 and 319.22 ± 60.96 μm (P = 0.002) at month 3. Data on the 6-month follow-up showed a mild increase 398.33 ± 127.89 μm (P = 0.031). The mean (SD) change from baseline FT was 191.33 μm (a decrease value of 35%) at month 1, and 223.00 μm (decrease value of 41%) and 143.89 μm (decrease value of 26%) at month 3 and month 6, respectively. The baseline BCVA data were 0.62 ± 0.15 logarithm of the minimum angle of resolution (logMAR). The mean BCVA improved to 0.47 ± 0.21 logMAR (P = 0.008) and 0.37 ± 0.24 logMAR (P = 0.001) after month 1 and month 3, respectively. At the last visit (6-month follow-up), the mean BCVA was 0.37 ± 0.26 logMAR (P = 0.002). CONCLUSIONS: In this study, both mean FT and mean BCVA had improved from baseline by 1 month after treatment with a dexamethasone implant, and the improvement remained statistically significant throughout the 6-month study.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationInvest Ophthalmol Vis Sci. 2013 May 7;54(5):3320-4pt_PT
dc.identifier.doi10.1167/iovs.12-11463pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/2771
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectAdultpt_PT
dc.subjectAgedpt_PT
dc.subjectAged, 80 and overpt_PT
dc.subjectDexamethasonept_PT
dc.subjectDrug Implantspt_PT
dc.subjectFemalept_PT
dc.subjectFluorescein Angiographypt_PT
dc.subjectGlucocorticoidspt_PT
dc.subjectHumanspt_PT
dc.subjectIntravitreal Injectionspt_PT
dc.subjectMacular Edemapt_PT
dc.subjectMalept_PT
dc.subjectMiddle Agedpt_PT
dc.subjectPseudophakiapt_PT
dc.subjectRetrospective Studiespt_PT
dc.subjectTomography, Optical Coherencept_PT
dc.subjectTonometry, Ocularpt_PT
dc.subjectTreatment Outcomept_PT
dc.subjectVisual Acuitypt_PT
dc.subjectVitreous Bodypt_PT
dc.subjectCHLC OFTpt_PT
dc.titleDexamethasone Intravitreal Implant for Treatment of Patients with Recalcitrant Macular Edema Resulting from Irvine-Gass Syndromept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage3324pt_PT
oaire.citation.issue5pt_PT
oaire.citation.startPage3320pt_PT
oaire.citation.titleInvestigative Ophthalmology & Visual Sciencept_PT
oaire.citation.volume54pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IOVS 2013.pdf
Size:
265.25 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

OFT - Artigos